Impact of COVID-19 on Liver Transplantation in Hong Kong and Singapore: A Modelling Study

Tan, Ee Hong; Quek, Wei Liang; Suryadi,; Chahed, Haroun; Iyer, Shridhar Ganpathi; Jeyaraj, Prema Raj; Lee, Guan Huei; Chan, Albert; Cheng, Stephanie; Hoe, Jan; Tan, Ek Khoon; Chew, Lock Yue; Fung, James; Chen, Melvin; Muthiah, Mark; Huang, Daniel Q.

doi:10.1016/j.lanwpc.2021.100262

Cited by 5 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Among patients with COVID-19 and chronic liver disease in the US National COVID Cohort Collaborative, the presence of cirrhosis was associated with an increased risk of mortality (adjusted HR 3.3) 129 . In the early phase of the COVID-19 pandemic, cirrhosis referrals, hospitalizations and clinic visits declined substantially, which might have contributed to lower quality of care, delayed presentation and loss of follow-up 95 , 96 , 130 , 131 . A global study conducted at 44 international centres determined that consultations, testing and treatment rates for hepatitis B virus and hepatitis C virus infection decreased substantially between January 2019 and December 2020, and this decrease was related to the COVID-19 pandemic 89 .…”

Section: Predictionsmentioning

confidence: 99%

See 1 more Smart Citation

Global epidemiology of cirrhosis — aetiology, trends and predictions

Huang

Terrault

Tacke

et al. 2023

Nat Rev Gastroenterol Hepatol

Self Cite

257

View full text Add to dashboard Cite

Cirrhosis is an important cause of morbidity and mortality in people with chronic liver disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to the rising prevalence of obesity and increased alcohol consumption on the one hand, and improvements in the management of hepatitis B virus and hepatitis C virus infections on the other, the epidemiology and burden of cirrhosis are changing. In this Review, we highlight global trends in the epidemiology of cirrhosis, discuss the contributions of various aetiologies of liver disease, examine projections for the burden of cirrhosis, and suggest future directions to tackle this condition. Although viral hepatitis remains the leading cause of cirrhosis worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) and alcohol-associated cirrhosis are rising in several regions of the world. The global number of deaths from cirrhosis increased between 2012 and 2017, but age-standardized death rates (ASDRs) declined. However, the ASDR for NAFLD-associated cirrhosis increased over this period, whereas ASDRs for other aetiologies of cirrhosis declined. The number of deaths from cirrhosis is projected to increase in the next decade. For these reasons, greater efforts are required to facilitate primary prevention, early detection and treatment of liver disease, and to improve access to care.

show abstract

Section: Predictionsmentioning

confidence: 99%

“…In the early phase of the COVID-19 pandemic, cirrhosis referrals, hospitalizations and clinic visits declined substantially, which might have contributed to lower quality of care, delayed presentation and loss of follow-up 95 , 96 , 130 , 131 .…”

Section: Predictionsmentioning

confidence: 99%

Global epidemiology of cirrhosis — aetiology, trends and predictions

Huang

Terrault

Tacke

et al. 2023

Nat Rev Gastroenterol Hepatol

Self Cite

257

View full text Add to dashboard Cite

show abstract

“…Forty-four studies reported clinical outcomes such as mortality and morbidity. 2 4-6 10 12-17 20 21 23-37 39-46 49-52 [54][55][56][57] Fifteen studies reported public health goal outcomes (eg, delay in reaching disease elimination targets). 11 18 19 25 26 33 35 37 44 47 48 53 54 56 57 Seventeen articles reported humanistic outcomes (such as change in risky behaviour 2 5 12 14 16 20 21 23 24 29 35 41 43 49 50 52 and quality of life 28 ) and four articles 22 29 35 38 reported economic outcome (eg, financial loss).…”

Section: Effects Of Covid-19 Disruptions Modelledmentioning

confidence: 99%

Scoping review of modelling studies assessing the impact of disruptions to essential health services during COVID-19

Veettil,

Schwerer,

Kategeaw

et al. 2023

BMJ Open

View full text Add to dashboard Cite

BackgroundStudies assessing the indirect impact of COVID-19 using mathematical models have increased in recent years. This scoping review aims to identify modelling studies assessing the potential impact of disruptions to essential health services caused by COVID-19 and to summarise the characteristics of disruption and the models used to assess the disruptions.MethodsEligible studies were included if they used any models to assess the impact of COVID-19 disruptions on any health services. Articles published from January 2020 to December 2022 were identified from PubMed, Embase and CINAHL, using detailed searches with key concepts including COVID-19, modelling and healthcare disruptions. Two reviewers independently extracted the data in four domains. A descriptive analysis of the included studies was performed under the format of a narrative report.ResultsThis scoping review has identified a total of 52 modelling studies that employed several models (n=116) to assess the potential impact of disruptions to essential health services. The majority of the models were simulation models (n=86; 74.1%). Studies covered a wide range of health conditions from infectious diseases to non-communicable diseases. COVID-19 has been reported to disrupt supply of health services, demand for health services and social change affecting factors that influence health. The most common outcomes reported in the studies were clinical outcomes such as mortality and morbidity. Twenty-five studies modelled various mitigation strategies; maintaining critical services by ensuring resources and access to services are found to be a priority for reducing the overall impact.ConclusionA number of models were used to assess the potential impact of disruptions to essential health services on various outcomes. There is a need for collaboration among stakeholders to enhance the usefulness of any modelling. Future studies should consider disparity issues for more comprehensive findings that could ultimately facilitate policy decision-making to maximise benefits to all.

show abstract

“…The former was divided into 5 subgroups, including diagnosis of HCC in medical centres [16][17][18][19][20][21][22], activities of diagnostic centres and pathology laboratories [23][24][25], delay in diagnosis [18], screening method [26], and risk of HCC in patients with related alcohol-related hepatitis [27]. The latter was divided into 13 subgroups, including delaying or stopping treatment activities [18,19,22,[28][29][30], activities of medical centres [26,28,[31][32][33], modifying treatment methods [18,19,29,34], LT in patients with HCC [25,29,[35][36][37], visiting and consulting patients [18,19,22,25,26,29,33,38], hospitalization [29], performing treatment methods [19,25,29,33,…”

Section: Characteristics Of Included Studies and Quality Assessmentmentioning

confidence: 99%

Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review

Mazidimoradi,

Sabet Birjandi,

Salehiniya

2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Aim: Changes in strategies in the coronavirus disease 2019 (COVID-19) crisis and the imposing of restrictions have isolated many vulnerable patients including those with hepatocellular carcinoma (HCC) from routine medical care. This study investigated how the COVID-19 pandemic is affecting the diagnosis and treatment of HCC. Methods: An extensive search was conducted in the PubMed, Scopus, and Web of Science databases by using the appropriate keywords: COVID-19, hepatocellular carcinoma, hepatocellular cancer, and MeSH. Studies in English related to the purpose of the study were included in the analysis, and review studies, case reports, letters to editors, comments, and reports were excluded. The quality of the studies was assessed by the “Adapted Newcastle-Ottawa Quality Assessment Scales” checklist. The Endnote X7 software has been used for managing items. Results: The final qualitative analysis consisted of 27 articles. During the COVID-19 crisis, HCC diagnosis decreased from 20% to 34.13% compared to pre-crisis. The impact of the COVID-19 pandemic on HCC treatment encompasses a wide range of aspects. Generally, delays in treatment for patients with HCC ranged from more than one month for 21.5% of patients in France, to two months for 26% of patients in Italy, up to 30% in Austria, and 66.7% in Asia-Pacific countries. Conclusions: According to the findings, developing and implementing appropriate diagnostic and therapeutic strategies and developing low-cost and high-precision screening programs among high-risk populations seem to be effective in reducing the impact of the COVID-19 pandemic on HCC management.

show abstract

Impact of COVID-19 on Liver Transplantation in Hong Kong and Singapore: A Modelling Study

Cited by 5 publications

References 31 publications

Global epidemiology of cirrhosis — aetiology, trends and predictions

Global epidemiology of cirrhosis — aetiology, trends and predictions

Scoping review of modelling studies assessing the impact of disruptions to essential health services during COVID-19

Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review

Contact Info

Product

Resources

About